BR112018071467A2 - método de tratamento ou prevenção de patologias hepáticas - Google Patents

método de tratamento ou prevenção de patologias hepáticas

Info

Publication number
BR112018071467A2
BR112018071467A2 BR112018071467A BR112018071467A BR112018071467A2 BR 112018071467 A2 BR112018071467 A2 BR 112018071467A2 BR 112018071467 A BR112018071467 A BR 112018071467A BR 112018071467 A BR112018071467 A BR 112018071467A BR 112018071467 A2 BR112018071467 A2 BR 112018071467A2
Authority
BR
Brazil
Prior art keywords
prevention
treatment
liver disorders
individual
signaling
Prior art date
Application number
BR112018071467A
Other languages
English (en)
Inventor
Falkevall Annelie
Mehlem Annika
Palombo Isolde
Eriksson Ulf
Original Assignee
B Creative Sweden Ab
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016901483A external-priority patent/AU2016901483A0/en
Application filed by B Creative Sweden Ab, Csl Ltd filed Critical B Creative Sweden Ab
Publication of BR112018071467A2 publication Critical patent/BR112018071467A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente divulgação fornece um método de tratamento de uma doença de esteatose hepática não alcóolica num indivíduo, em que o método compreende administrar ao indivíduo um composto que inibe a sinalização de vegf-b.
BR112018071467A 2016-04-21 2017-04-21 método de tratamento ou prevenção de patologias hepáticas BR112018071467A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016901483A AU2016901483A0 (en) 2016-04-21 Methods of treating or preventing liver conditions
AU2016901494A AU2016901494A0 (en) 2016-04-21 Method of treating or preventing liver conditions
PCT/AU2017/050364 WO2017181243A1 (en) 2016-04-21 2017-04-21 Method of treating or preventing liver conditions

Publications (1)

Publication Number Publication Date
BR112018071467A2 true BR112018071467A2 (pt) 2019-02-05

Family

ID=60115684

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018071467A BR112018071467A2 (pt) 2016-04-21 2017-04-21 método de tratamento ou prevenção de patologias hepáticas

Country Status (10)

Country Link
US (2) US20190119369A1 (pt)
EP (1) EP3445450A4 (pt)
JP (1) JP7065786B2 (pt)
KR (1) KR102513989B1 (pt)
CN (1) CN109310884B (pt)
AU (1) AU2017254775B2 (pt)
BR (1) BR112018071467A2 (pt)
CA (1) CA3020988A1 (pt)
RU (2) RU2021136970A (pt)
WO (1) WO2017181243A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2718326T3 (da) 2011-06-13 2020-10-26 Csl Ltd Antistoffer mod g-csfr og anvendelser deraf
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
EP3717011B1 (en) * 2017-11-29 2022-12-07 CSL Limited Method of treating or preventing ischemia-reperfusion injury
WO2020056459A1 (en) * 2018-09-18 2020-03-26 Csl Limited Method of treating wasting disorders
IT201900005700A1 (it) * 2019-04-12 2020-10-12 Metadeq Ltd Nuovo marcatore di patologia e suoi usi
CN112010971A (zh) * 2019-05-30 2020-12-01 义慧科技(深圳)有限公司 抗vegf抗体在制备预防和/或治疗脂肪肝的药物中的应用
KR102280261B1 (ko) * 2019-07-16 2021-07-20 이화여자대학교 산학협력단 대사체 분석을 이용한 간질환의 진단 방법
CN114470000A (zh) * 2020-11-11 2022-05-13 上海萨美细胞技术有限公司 无细胞脂肪提取液对非酒精性脂肪肝炎的治疗用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822644B2 (en) * 2004-08-02 2014-09-02 Zenyth Operations Pty Ltd Method of treating cancer comprising a VEGF-B antagonist
ES2497641T3 (es) * 2006-05-17 2014-09-23 The Ludwig Institute For Cancer Research Dirección a la regulación de VEGF-B de transportadores de ácidos grasos para modular enfermedades humanas
AU2013224763B2 (en) * 2006-05-17 2016-06-30 Ludwig Institute For Cancer Research Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
US20080194575A1 (en) * 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
WO2009045356A2 (en) * 2007-09-28 2009-04-09 Yale University Microrna compositions in the treatment of vegf-mediated disorders
WO2009126698A2 (en) 2008-04-09 2009-10-15 Ludwig Institute For Cancer Research Regulation of fatty acid transporters
WO2015077845A1 (en) * 2013-11-28 2015-06-04 Csl Limited Method of treating nephropathy
EP3082860B1 (en) * 2013-12-18 2020-11-25 CSL Limited Method of treating wounds

Also Published As

Publication number Publication date
US20240002488A1 (en) 2024-01-04
US20190119369A1 (en) 2019-04-25
RU2021136970A (ru) 2022-04-01
EP3445450A1 (en) 2019-02-27
KR102513989B1 (ko) 2023-03-24
RU2018139893A3 (pt) 2020-06-25
AU2017254775A1 (en) 2018-11-08
WO2017181243A1 (en) 2017-10-26
CN109310884B (zh) 2022-10-28
AU2017254775B2 (en) 2023-06-29
CA3020988A1 (en) 2017-10-26
KR20180135928A (ko) 2018-12-21
CN109310884A (zh) 2019-02-05
RU2018139893A (ru) 2020-05-21
JP2019514875A (ja) 2019-06-06
EP3445450A4 (en) 2020-01-08
JP7065786B2 (ja) 2022-05-12

Similar Documents

Publication Publication Date Title
BR112018071467A2 (pt) método de tratamento ou prevenção de patologias hepáticas
MX2019003447A (es) Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma.
BR112018004620A2 (pt) moduladores da expressão de kras
EP3785728A3 (en) Use of myostatin inhibitors and combination therapies
EA201790398A1 (ru) Способы лечения заболевания печени
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
BR112017024684A2 (pt) compostos coagonistas de glucagon e glp-1
MX2019006864A (es) Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de factor de necrosis tumoral (tnf).
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
MX2018002049A (es) Diacereina o sus analogos para inhibir la expresion de proteina como mota relacionada a la apoptosis que contiene un dominio de reclutamiento de caspasa (asc), expresion de dominios de pirina y familia nlr que contienen 3 (nlrp3) y/o formacion de complejo de inflamasoma de nlrp3.
BR112017011900A2 (pt) tratamento de ataques com fosfatase alcalina recombinante
BR112018014222A2 (pt) método de tratamento da glomerulopatia c3
BR112017018092A2 (pt) composto, composição farmacêutica, e, método para tratar e/ou prevenir uma doença ou distúrbio.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MD4801C1 (ro) Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
BR112018013522A2 (pt) compostos inibidores de metaloenzima
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
WO2015127134A3 (en) Complement component c5 antibodies
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
IN2015DN00438A (pt)
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]